Mary Lou Hayden, RN, MS, FNP-C, AE-C, Chair
Clinical Assistant Professor
University of Virginia
Asthma and Allergy Nurse Practitioner
Virginia Adult and Pediatric Allergy and Asthma
Todd A. Mahr, MD
Director, Pediatric Allergy/Asthma
Gundersen Lutheran Medical Center
Department of Pediatrics
University of Wisconsin School of Medicine and Public Health
1.5 contact hours (which includes .25 hour of pharmacology)
CREDIT FOR THIS PROGRAM IS AVAILABLE FOR NURSE PRACTITIONERS ONLY.
Up to 40% of Americans suffer from some form of allergic rhinitis, a syndrome often characterized by a collection of symptoms that include sneezing, nasal congestion, nasal itching, and rhinorrhea. When poorly controlled, the condition is often associated with other comorbidities, such as asthma and sinusitis. Allergic rhinitis and its comorbidities significantly affect the quality of life in those affected by restricting the patient’s daily activities. This results in decreases in performance and productivity while at school or work and increases in absenteeism. Even though people spend billions of dollars annually on physician visits, prescription medications, and over-the-counter medications to remedy their symptoms, only a quarter of those patients feel that their symptoms are well controlled. Additionally, accurate diagnosis of rhinitis directs treatment, so clinicians need to be familiar with the proper classification scheme used in rhinitis syndromes. Using a case-based approach, this activity will help nurse practitioners to appropriately identify and classify their patients’ rhinitis. Suitable medications and their role in the treatment of allergic rhinitis will also be discussed. Program Developer/Facilitator
. Target Audience
This program is designed for nurse practitioners caring for patients with allergic rhinitis.
Upon completion of this educational activity, the participant should be able to:
Discuss the prevalence of allergic rhinitis and nonallergic rhinitis.
Recognize the burden of allergic rhinitis.
Describe the appropriate diagnosis and classification of rhinitis.
Develop an appropriate treatment plan for allergic rhinitis.
It is AANP's goal to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. To meet this goal, both real and/or potential conflicts of interest must be considered during the development of a continuing educational activity. All individuals having control over the development of an activity’s content and all faculty participating in AANP programs are expected to disclose any relationships they may have with commercial companies whose products or services may be mentioned. Potential learners will be informed of all disclosed relationships. The following are all disclosures for this CE program.
Mary Lou Hayden, RN, MS, FNP, APRN, AE-C discloses that she is a member of speakers’ bureaus for Schering-Plough, Genentech, and AstraZeneca, and advisory committees for Genentech, sanofi-aventis, and AstraZeneca.
Todd A. Mahr, MD discloses that he has received honoraria, consultant fees, and research support, and is a member of speakers’ bureaus for GlaxoSmithKline, Alcon Laboratories, Genentech, Merck, Novartis, Schering-Plough, sanofi-aventis, and Verus Pharmaceuticals.
This program is approved for 1.5 contact hours of continuing education (which includes .25 hour of pharmacology) by the American Academy of Nurse Practitioners. Program ID: 708384.
Commercial Support Statements
Supported by an educational grant from Schering-Plough.
AANP and Medical Communications Media, Inc. (MCM) gratefully acknowledge the educational grant provided by Schering-Plough for this web-based educational program. The view and opinions expressed in this program are those of the faculty and do not necessarily reflect the view of AANP or MCM.